Contents
Clinical trial facilities in Washington offer people the chance to take part in research studies that can shape the field of medicine. The state is home to many reputable facilities, such as the Northwest Clinical Research Center and Rainier Clinical Research Center.
Washington is one of the strongest research states in the country. As of July 2026, 1,682 studies are actively recruiting volunteers statewide, according to ClinicalTrials.gov, anchored by the University of Washington, Fred Hutchinson Cancer Center, and Seattle Children’s Hospital. Dedicated research sites such as Northwest Clinical Research Center in Bellevue also run paid studies year-round.
Quick Facts: Paid Clinical Trials in Washington
- Actively recruiting studies (July 2026): 1,682 (ClinicalTrials.gov)
- Typical compensation: $50–$100 per completed outpatient visit; residential Phase 1 studies pay more (see highest paid clinical trials)
- Cost to participate: $0 — study care and visits are covered by the sponsor
- Worth knowing: Seattle Children’s is the state’s most active trial site — pediatric and family studies are a Washington strength
What’s being studied in Washington right now
We sampled recruiting Washington studies on ClinicalTrials.gov in July 2026. The most active sites and most-studied conditions:
| Most active research sites | Most-studied conditions |
|---|---|
| Seattle Children’s Hospital (103 site listings) | Breast cancer |
| University of Washington (100) | Acute myeloid leukemia |
| Fred Hutchinson Cancer Center (137 incl. UW consortium) | Multiple myeloma |
| Swedish Medical Center, Seattle (48) | Ovarian and prostate cancer |
Washington stands out for pediatric research: Seattle Children’s is the single most active trial site in the state, so families have more study options here than in most of the country.
Clinical Trials For Disease Areas in Washington
Clinical research trials in Washington carry out a wide range of research protocols. That includes drug testing, treatment, and development of medical devices.
With innovative delivery approaches, patients can get better treatment results for problems like heart disease, diabetes, musculoskeletal conditions, and infectious diseases.
Seattle’s research pedigree runs deep: Fred Hutchinson Cancer Center pioneered bone marrow transplantation, work that earned E. Donnall Thomas the 1990 Nobel Prize in Medicine and grew into today’s cancer immunotherapy programs.
You too can make a lasting impact on healthcare. Volunteer for a clinical trial today!
Consent for Use of Stored Patient Specimens for Future Testing
Recruiting
The purpose of this study is to obtain informed consent to use stored human biological materials (HBM) (e.g., blood and other tissues) for future studies that may include genetic testing.
The purpose of this study is to obtain informed consent to use stored human biological materials (HBM) (e.g., blood and other tissues) for future studies that may include genetic testing. Read Less
Gender:
ALL
Ages:
All
Trial Updated:
09/20/2024
Locations: Univ of Washington, Seattle, Washington
Univ of Washington, Seattle, Washington
Conditions: HIV Infections
A Prospective Database of Infants With Cholestasis
Recruiting
Biliary atresia, idiopathic neonatal hepatitis, and specific genetic cholestatic conditions are the most common causes of jaundice and hyperbilirubinemia that continue beyond the newborn period. The long term goal of the Childhood Liver Disease Research Network (ChiLDReN) is to establish a database of clinical information and plasma, serum, and tissue samples from cholestatic children to facilitate research and to perform clinical, epidemiological and therapeutic trials in these important pediat... Read More
Biliary atresia, idiopathic neonatal hepatitis, and specific genetic cholestatic conditions are the most common causes of jaundice and hyperbilirubinemia that continue beyond the newborn period. The long term goal of the Childhood Liver Disease Research Network (ChiLDReN) is to establish a database of clinical information and plasma, serum, and tissue samples from cholestatic children to facilitate research and to perform clinical, epidemiological and therapeutic trials in these important pediatric liver diseases. Read Less
Gender:
ALL
Ages:
6 months and below
Trial Updated:
05/19/2025
Locations: Seattle Children's Hospital, Seattle, Washington
Seattle Children's Hospital, Seattle, Washington
Conditions: Biliary Atresia, Neonatal Cholestasis
Apheresis and Specimen Collection Procedures to Obtain Plasma, Peripheral Blood Mononuclear Cells (PBMCs) and Other Specimens for Research Studies
Recruiting
This study collects specimens from volunteers for use in studies by NIAID's Vaccine Research Center. A number of different types of specimens or samples can be collected, including blood, urine, body fluids or secretions, skin swabs, or skin biopsies. The samples are used for medical research, including the study of HIV, hepatitis, and other diseases; immune system responses, such as responses to vaccinations or infections; and for research on vaccine development.
Blood samples may be collected... Read More
This study collects specimens from volunteers for use in studies by NIAID's Vaccine Research Center. A number of different types of specimens or samples can be collected, including blood, urine, body fluids or secretions, skin swabs, or skin biopsies. The samples are used for medical research, including the study of HIV, hepatitis, and other diseases; immune system responses, such as responses to vaccinations or infections; and for research on vaccine development.
Blood samples may be collected either by ordinary blood drawing (phlebotomy) or by apheresis, a procedure for collecting a larger quantity of blood cells or plasma than would be possible through simple blood drawing. For this procedure, the participant lies on a recliner or couch. Blood is removed through a needle in the vein of one arm and spun in a machine that separates out the desired component (plasma or white blood cells). The remainder of the blood is returned either through the same needle or through a needle in the other arm. The procedure takes about 1 to 3 hours.
Volunteers who are 18 years of age and older, including participants in other NIH research protocols, may be eligible. Individuals who have a condition that the research staff considers a reason not to make a sample donation will be excluded from the study.
Participants may have only one sample collected or may be asked to undergo repetitive sample collection procedures, depending upon the requirements of the particular research project for which the samples are being collected. Each individual's enrollment is for a 1-year period, which can be extended. Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/15/2025
Locations: EvergreenHealth Medical Center, Kirkland, Washington
EvergreenHealth Medical Center, Kirkland, Washington
Conditions: Sample Collection
TrialNet Pathway to Prevention of T1D
Recruiting
Rationale:
The accrual of data from the laboratory and from epidemiologic and prevention trials has improved the understanding of the etiology and pathogenesis of type 1 diabetes mellitus (T1DM). Genetic and immunologic factors play a key role in the development of T1DM, and characterization of the early metabolic abnormalities in T1DM is steadily increasing. However, information regarding the natural history of T1DM remains incomplete. The TrialNet Natural History Study of the Development of T... Read More
Rationale:
The accrual of data from the laboratory and from epidemiologic and prevention trials has improved the understanding of the etiology and pathogenesis of type 1 diabetes mellitus (T1DM). Genetic and immunologic factors play a key role in the development of T1DM, and characterization of the early metabolic abnormalities in T1DM is steadily increasing. However, information regarding the natural history of T1DM remains incomplete. The TrialNet Natural History Study of the Development of T1DM (Pathway to Prevention Study) has been designed to clarify this picture, and in so doing, will contribute to the development and implementation of studies aimed at prevention of and early treatment in T1DM.
Purpose:
TrialNet is an international network dedicated to the study, prevention, and early treatment of type 1 diabetes. TrialNet sites are located throughout the United States, Canada, Finland, United Kingdom, Italy, Germany, Sweden, Australia, and New Zealand. TrialNet is dedicated to testing new approaches to the prevention of and early intervention for type 1 diabetes.
The goal of the TrialNet Natural History Study of the Development of Type 1 Diabetes is to enhance our understanding of the demographic, immunologic, and metabolic characteristics of individuals at risk for developing type 1 diabetes.
The Natural History Study will screen relatives of people with type 1 diabetes to identify those at risk for developing the disease. Relatives of people with type 1 diabetes have about a 5% percent chance of being positive for the antibodies associated with diabetes. TrialNet will identify adults and children at risk for developing diabetes by testing for the presence of these antibodies in the blood. A positive antibody test is an early indication that damage to insulin-secreting cells may have begun. If this test is positive, additional testing will be offered to determine the likelihood that a person may develop diabetes. Individuals with antibodies will be offered the opportunity for further testing to determine their risk of developing diabetes over the next 5 years and to receive close monitoring for the development of diabetes. Read Less
Gender:
ALL
Ages:
Between 2 years and 45 years
Trial Updated:
06/30/2025
Locations: Benaroya Research Institute, Seattle, Washington
Benaroya Research Institute, Seattle, Washington
Conditions: Diabetes Mellitus, Type 1
Mucopolysaccharidosis I (MPS I) Registry
Recruiting
The Mucopolysaccharidosis I (MPS I) Registry is an ongoing, observational database that tracks the outcomes of patients with MPS I. The data collected by the MPS I Registry will provide information to better characterize the natural history and progression of MPS I as well as the clinical responses of patients receiving enzyme replacement therapy, such as Aldurazyme (Recombinant Human Alpha-L-Iduronidase), or other treatment modalities.
The objectives of the Registry are:
* To evaluate the lon... Read More
The Mucopolysaccharidosis I (MPS I) Registry is an ongoing, observational database that tracks the outcomes of patients with MPS I. The data collected by the MPS I Registry will provide information to better characterize the natural history and progression of MPS I as well as the clinical responses of patients receiving enzyme replacement therapy, such as Aldurazyme (Recombinant Human Alpha-L-Iduronidase), or other treatment modalities.
The objectives of the Registry are:
* To evaluate the long-term effectiveness and safety of Aldurazyme® (laronidase)
* To characterize and describe the MPS I population as a whole, including the variability, progression, and natural history of MPS I
* To help the MPS I medical community with the development of recommendations for monitoring patients and reports on patient outcomes to optimize patient care Read Less
Gender:
ALL
Ages:
All
Trial Updated:
11/19/2024
Locations: Seattle Children's Hospital- Site Number : 840028, Seattle, Washington +2 locations
Seattle Children's Hospital- Site Number : 840028, Seattle, Washington
University Of Washington Medical Center- Site Number : 840059, Seattle, Washington
Multicare Health System ¿ Mary Bridge Childrens Hospital- Site Number : 840115, Tacoma, Washington
Conditions: Mucopolysaccharidosis I (MPS I)
Fabry Disease Registry & Pregnancy Sub-registry
Recruiting
The Fabry Registry is an ongoing, international multi-center, strictly observational program that tracks the routine clinical outcomes for patients with Fabry disease, irrespective of treatment status. No experimental intervention is involved; patients in the Registry undergo clinical assessments and receive care as determined by the patient's treating physician.
The primary objectives of the Registry are:
* To enhance the understanding of the variability, progression, and natural history of F... Read More
The Fabry Registry is an ongoing, international multi-center, strictly observational program that tracks the routine clinical outcomes for patients with Fabry disease, irrespective of treatment status. No experimental intervention is involved; patients in the Registry undergo clinical assessments and receive care as determined by the patient's treating physician.
The primary objectives of the Registry are:
* To enhance the understanding of the variability, progression, and natural history of Fabry disease, including heterozygous females with the disease;
* To assist the Fabry medical community with the development of recommendations for monitoring patients and reports on patient outcomes to help optimize patient care;
* To characterize and describe the Fabry population as a whole;
* To evaluate the long-term safety and effectiveness of Fabrazyme®
Fabry Pregnancy Sub-registry: This Sub-registry is a multicenter, international, longitudinal, observational, and voluntary program designed to track pregnancy outcomes for any pregnant woman enrolled in the Fabry Registry, regardless of whether she is receiving disease-specific therapy (such as enzyme replacement therapy with agalsidase beta) and irrespective of the commercial product with which she may be treated. Data from the Sub-registry are also used to fulfill various global regulatory requirements, to support product development/reimbursement, and for other research and non-research-related purposes. No experimental intervention is given; thus a patient will undergo clinical assessments and receive standard of care treatment as determined by the patient's physician. If a patient consents to this Sub-registry, information about the patient's medical and obstetric history, pregnancy, and birth will be collected, and, if a patient consents to data collection for her infant, data on infant growth through month 36 postpartum will be collected. Read Less
Gender:
ALL
Ages:
All
Trial Updated:
08/07/2025
Locations: Seattle Children's Hospital- Site Number : 840028, Seattle, Washington +2 locations
Seattle Children's Hospital- Site Number : 840028, Seattle, Washington
University Of Washington Medical Center- Site Number : 840059, Seattle, Washington
Multicare Health System ¿ Mary Bridge Childrens Hospital- Site Number : 840115, Tacoma, Washington
Conditions: Fabry Disease
Pompe Disease Registry Protocol
Recruiting
The Pompe Registry is a global, multicenter, international, longitudinal, observational, and voluntary program for patients with Pompe disease, designed to track the disease's natural history and outcomes in patients, both treated and not. Data from the Registry are also used to fulfill various global regulatory commitments, to support product development/reimbursement, and for other research and non-research related purposes.
The objectives of the Registry are:
* To enhance understanding of t... Read More
The Pompe Registry is a global, multicenter, international, longitudinal, observational, and voluntary program for patients with Pompe disease, designed to track the disease's natural history and outcomes in patients, both treated and not. Data from the Registry are also used to fulfill various global regulatory commitments, to support product development/reimbursement, and for other research and non-research related purposes.
The objectives of the Registry are:
* To enhance understanding of the variability, progression, identification, and natural history of Pompe disease, with the ultimate goal of better guiding and assessing therapeutic intervention.
* To assist the Pompe medical community with the development of recommendations for monitoring patients, and to provide reports on patient outcomes, to optimize patient care.
* To characterize the Pompe disease population.
* To evaluate the long-term effectiveness of alglucosidase alfa. Read Less
Gender:
ALL
Ages:
All
Trial Updated:
08/06/2025
Locations: Seattle Children's Hospital- Site Number : 840028, Seattle, Washington +2 locations
Seattle Children's Hospital- Site Number : 840028, Seattle, Washington
University Of Washington Medical Center- Site Number : 840059, Seattle, Washington
Multicare Health System ¿ Mary Bridge Childrens Hospital- Site Number : 840115, Tacoma, Washington
Conditions: Glycogen Storage Disease Type II, Pompe Disease
Longitudinal Study of Urea Cycle Disorders
Recruiting
Urea cycle disorders (UCD) are a group of rare inherited metabolism disorders. Infants and children with UCD commonly experience episodes of vomiting, lethargy, and coma. The purpose of this study is to perform a long-term analysis of a large group of individuals with various UCDs. The study will focus on the natural history, disease progression, treatment, and outcome of individuals with UCD.
Urea cycle disorders (UCD) are a group of rare inherited metabolism disorders. Infants and children with UCD commonly experience episodes of vomiting, lethargy, and coma. The purpose of this study is to perform a long-term analysis of a large group of individuals with various UCDs. The study will focus on the natural history, disease progression, treatment, and outcome of individuals with UCD. Read Less
Gender:
ALL
Ages:
All
Trial Updated:
02/10/2024
Locations: Children's Hospital and Regional Medical Center, Seattle, Washington
Children's Hospital and Regional Medical Center, Seattle, Washington
Conditions: Brain Diseases, Metabolic, Inborn, Amino Acid Metabolism, Inborn Errors, Urea Cycle Disorders
Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products
Recruiting
The main purpose of the Product Performance Report (formerly referred to as System Longevity Study) is to evaluate long-term performance of Medtronic market-released cardiac rhythm products by analyzing product survival probabilities.
The main purpose of the Product Performance Report (formerly referred to as System Longevity Study) is to evaluate long-term performance of Medtronic market-released cardiac rhythm products by analyzing product survival probabilities. Read Less
Gender:
ALL
Ages:
All
Trial Updated:
07/29/2025
Locations: Not set, Olympia, Washington +1 locations
Not set, Olympia, Washington
Not set, Spokane, Washington
Conditions: Arrhythmia, Bradycardia, Heart Failure, Sinus Tachycardia
Genetic Determinants of Barrett's Esophagus and Esophageal Adenocarcinoma
Recruiting
The overall objectives of this BETRNet Research Center (RC) are:
1. to conduct a rigorous, integrated spectrum of transdisciplinary human research in Barrett's esophagus (BE) and esophageal adenocarcinoma (ECA)
2. to increase the biological understanding of key observations made by our clinical researchers;
3. to translate knowledge derived from genetic, epigenetic, and transcriptome research to solving clinical dilemmas in detection, prognosis, prevention, and therapy of BE in order to prevent... Read More
The overall objectives of this BETRNet Research Center (RC) are:
1. to conduct a rigorous, integrated spectrum of transdisciplinary human research in Barrett's esophagus (BE) and esophageal adenocarcinoma (ECA)
2. to increase the biological understanding of key observations made by our clinical researchers;
3. to translate knowledge derived from genetic, epigenetic, and transcriptome research to solving clinical dilemmas in detection, prognosis, prevention, and therapy of BE in order to prevent EAC and improve the outcomes of EAC;
4. to foster a transdisciplinary and translation research culture and to effectively expand and enhance scientific research focused on BE and EAC;
5. to evaluate research and transdisciplinary programs and to continuously improve research, productivity and enhance translational implementation. These objectives build and synergize on existing multi-institutional collaborative networks and the considerable clinical, basic science, and translational expertise available at our institutions, focusing on improving the outcomes of patients with BE and EAC. The overarching organization framework for this RC proposal is 1) to focus laboratory research on understanding the genetic susceptibility, genomic and epigenetic changes that influence the development of BE and EAC; and 2) to then translate laboratorydiscoveries into clinical applications for effective detection, molecular risk stratification, and prevention of progression from BE to EAC. Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/16/2025
Locations: VA Puget Sound Health Care System, Seattle, Washington +1 locations
VA Puget Sound Health Care System, Seattle, Washington
Fred Hutchinson Cancer Research Center, UWMC, Seattle, Washington
Conditions: Barrett's Esophagus, Esophageal Neoplasm
Paid Clinical Trials in Washington
Patient care costs are the costs you would need to pay if you didn’t participate in a trial. Such as lab tests, doctor appointments, X-rays, and more. When people participate in paid clinical trials in Washington, they get monetary or non-monetary compensation.
If you need to travel to participate in WA paid clinical trials, then you can get reimbursements for lodging, parking, travel, meals, etc. This financial help can be highly beneficial for those who can’t afford treatment.
Clinical Trials For Health Volunteers in Washington
When research teams in Washington develop a new technique, such as an imaging device or a new drug, they need health volunteers to get proper results. Your data becomes the healthy baseline that patient results are measured against.
Your commitment counts. Apply for a study below and help move new treatments forward!
Auditory Prediction and Error Evaluation in the Speech of Individuals Who Stutter
Recruiting
Stuttering negatively impacts communication and reduces the overall quality of life and well-being of individuals who stutter. This study will provide a strong foundation for developing neural and behavioral interventions for stuttering. Participants will be asked to name pictures, read words/sentences silently or aloud, and listen to speech and nonspeech sounds while their speech, muscle, and brain signals are collected. Some participants may also receive brain stimulation while reading and spe... Read More
Stuttering negatively impacts communication and reduces the overall quality of life and well-being of individuals who stutter. This study will provide a strong foundation for developing neural and behavioral interventions for stuttering. Participants will be asked to name pictures, read words/sentences silently or aloud, and listen to speech and nonspeech sounds while their speech, muscle, and brain signals are collected. Some participants may also receive brain stimulation while reading and speaking. Read Less
Gender:
ALL
Ages:
3 years and above
Trial Updated:
08/19/2025
Locations: Univeristy of Washington, Seattle, Washington
Univeristy of Washington, Seattle, Washington
Conditions: Healthy Subjects, Stuttering, Developmental
Phase 2 Seattle Dietary Biomarkers Development Center
Recruiting
The Seattle Dietary Biomarker Development Center (S-DBDC) aims to advance the science of measuring dietary intake by identification and validation of dietary biomarkers that improve upon self-reported diet. To accomplish this mission, the Seattle DBDC will carry out controlled feeding studies in healthy human volunteers. Metabolomics assays will be conducted on blood and urine specimens collected during the feeding studies for biomarker identification. Stool samples will be collected and archive... Read More
The Seattle Dietary Biomarker Development Center (S-DBDC) aims to advance the science of measuring dietary intake by identification and validation of dietary biomarkers that improve upon self-reported diet. To accomplish this mission, the Seattle DBDC will carry out controlled feeding studies in healthy human volunteers. Metabolomics assays will be conducted on blood and urine specimens collected during the feeding studies for biomarker identification. Stool samples will be collected and archived. Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/18/2025
Locations: Fred Hutchinson Cancer Center, Seattle, Washington
Fred Hutchinson Cancer Center, Seattle, Washington
Conditions: Healthy Adults
Washington Paid Clinical Trial FAQs
-
How much do paid clinical trials pay in Washington?
Most outpatient studies in Washington pay $50–$100 per completed visit, plus travel reimbursement. Dedicated research units in the Seattle area run higher-paying residential studies. The exact amount appears in the consent form before you enroll.
-
Where are most clinical trials in Washington?
Seattle has the heaviest concentration: the University of Washington, Fred Hutchinson Cancer Center, Seattle Children’s, and Swedish Medical Center all run large programs, with dedicated research centers in Bellevue and Renton. Spokane and the Tri-Cities have options through regional health systems.
-
Can my child participate in a paid study in Washington?
Yes, with parental consent. Seattle Children’s Hospital is the most active research site in the state, and pediatric studies compensate families for time and travel. Children must also agree to take part when they are old enough to understand, a process called assent.
Medical Discoveries and Innovation in Washington
Many studies have helped shape the medicine of today. The state of Washington has been at the forefront of medical discoveries and clinical research for years. Here is a quick look at some of the most impactful achievements:
- COVID-19 Research: The Seattle Flu Study is a key component in studying the coronavirus. It became prominent for its efforts in early COVID-19 research and detection during the initial outbreak in the United States.
- Kidney Dialysis: Dr. Belding H. Scribner together with his colleagues, perfected the Scribner shunt. Dr. Scribner was a professor of Medicine University of Washington Seattle. He and his team helped launch the new era of modern renal replacement therapy.
- Vaccine Clinical Trials: The first human clinical trial for the Moderna vaccine began in Seattle. Research Professor Lisa Jackson and her team at the Kaiser Permanente Washington Health Research Institute are leading this effort.
Why Washington Is A Great Place For Clinical Research
Diversity is helpful. Washington state has a diverse population of patients. About 66% of its residents are White, 13.7% are Hispanic, 9.8% are Asian, 4.4% are Multiracial, 4.1% are Black, 1.2% are American Indian, and 0.7% are Native Hawaiian.